Johnson Financial Group LLC Boosts Stake in Immunome, Inc. (NASDAQ:IMNM)

Key Points

• Johnson Financial Group LLC increased its holdings in Immunome, Inc. by 140% in Q1, acquiring an additional 28,000 shares, bringing its total to 48,000 shares valued at $323,000.
• Several large institutional investors, including Primecap Management, increased their stakes significantly, with Primecap raising its holdings by 1,115.7% to 3,413,700 shares worth approximately $22.97 million.
• Immunome stock received mixed ratings from analysts, with a consensus of "Moderate Buy" and a target price averaging $23.14, despite experiencing a trading decline of 1.8% recently.

Johnson Financial Group LLC boosted its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 140.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,000 shares of the company's stock after acquiring an additional 28,000 shares during the period. Johnson Financial Group LLC owned 0.06% of Immunome worth $323,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of Immunome in the fourth quarter worth $274,000. Commonwealth Equity Services LLC purchased a new position in shares of Immunome in the fourth quarter worth $202,000. KLP Kapitalforvaltning AS purchased a new position in shares of Immunome in the fourth quarter worth $75,000. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock worth $6,888,000 after buying an additional 624,045 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after purchasing an additional 4,874 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime bought 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the transaction, the director directly owned 36,415 shares in the company, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.69% of the company's stock.

Wall Street Analyst Weigh In

IMNM has been the topic of a number of research reports. Wall Street Zen raised Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. cut their price objective on Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a report on Thursday. Finally, Wedbush reissued an "outperform" rating and issued a $21.00 price objective on shares of Immunome in a report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $23.14.

Immunome Stock Performance

Shares of Immunome stock traded down $0.18 during trading on Friday, hitting $9.69. 579,893 shares of the company's stock were exchanged, compared to its average volume of 808,887. The business has a 50-day simple moving average of $9.55 and a 200-day simple moving average of $8.90. Immunome, Inc. has a 52-week low of $5.15 and a 52-week high of $16.73. The stock has a market capitalization of $843.42 million, a price-to-earnings ratio of -3.15 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. On average, equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.